November 9, 2018

New publication confirms that the use of ProteoMediX proprietary blood-based biomarkers improves clinically significant prostate cancer diagnosis

Results of a new retrospective study analyzing ProteoMediX blood-based biomarkers have just been published in the British Journal of Urology International (Steuber et al. Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unneeded prostate biopsies. BJU Int 2018. doi:10.1111/bju.14540).

The study confirmed the pathological importance of the two cancer-related glycoproteins thrombospondin 1 (THBS1) and cathepsin D (CTSD) and showed that a model combiningthese two glycoproteins with precent free prostate specific antigen (%fPSA) improves the identification of subjects at risk of clinically relevant prostate cancer and may contribute to avoiding unnecessary prostate biopsies.

The publication is available on BJUI.